Extend Biosciences INC
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.0Mattributed |
|---|---|
| Latest round | strategic, $2.0M, 2024-01-01attributed |
| Founded | unknown |
| Headquarters | Newton, USA |
| Industry | bio |
| Stage | series-b+ |
| Website | extendbiosciences.com |
Extend Biosciences develops a vitamin D-conjugate platform that extends the half-life of peptide and small-molecule therapeutics. It serves rare endocrine disease patients and pharma partners licensing the conjugate platform. The DVITA technology binds drugs to circulating vitamin D-binding protein, extending dosing intervals from days to weeks.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | strategic | $2.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Strategic, $2.0M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $2.0M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | extendbiosciences.com, read 2026-05-02 |
| Description | self-reported | extendbiosciences.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.